EXPANSION INTO NEW LABORATORY SPACE

Guilford Street Laboratories announces expansion into new laboratory space at Kadans Science Partner, King’s Cross

London, UK - 15/4/26 - Guilford Street Laboratories (GSL) today announced a significant expansion of its laboratory infrastructure with the establishment of a new, stateoftheart laboratory space at Kadans Science Partner in King’s Cross, London. This milestone marks an important step in the company’s continued growth and scaling journey.

The new facility will significantly enhance GSL’s CoreLab capabilities, enabling faster, scalable, and precisiondriven diagnostic solutions for partners across clinical development and research programmes. Designed to support highthroughput and advanced analytical workflows, the laboratory will underpin GSL’s ability to deliver robust, highquality data at scale.

The expansion reflects GSL’s rapid growth in both research and clinical activity and supports the acceleration of its R&D operations, including the development and delivery of nextgeneration bloodbased diagnostic and immuneprofiling technologies.

Establishing a presence at Kadans Science Partner’s King’s Cross campus places GSL within a vibrant life sciences ecosystem and provides the infrastructure required to support its expanding portfolio of programmes and partnerships.

In parallel with the laboratory expansion, GSL plans continued growth of its team, with additional hires anticipated to strengthen research and development, CoreLab operations, and broader operational capacity.

Dr Tomas Baldwin, CEO of Guilford Street Laboratories, said:

"Expanding into a new laboratory space at Kadans marks a major milestone for GSL. This facility will enable us to scale our CoreLab capabilities and deliver faster, more precise diagnostic solutions for our partners. It represents an important step as we accelerate clinical development, expand our R&D activities, and prepare for the next stage of growth."

GSL looks forward to opening the doors to the new laboratory and beginning this next chapter of innovation, supporting partners across translational research, clinical validation, and realworld clinical delivery.